Literature DB >> 12164560

Cancers of the gallbladder and biliary ducts.

Kevin Yee1, Brett C Sheppard, John Domreis, Charles D Blanke.   

Abstract

Neoplasms of the biliary tract tree are uncommon and have a poor overall prognosis. Although numerous risk factors have been identified, little is known about the pathogenesis of these tumors, and no effective screening technique is available for early detection. Surgery remains the principal treatment modality and the only potential cure, with laparoscopy playing an increasingly important role in determining the resectability of these tumors. The role of postoperative adjuvant chemotherapy and radiation remains controversial. The efficacy of chemotherapy for advanced disease is relatively limited, with response rates of less than 10% for single-agent fluorouracil. Of the newer agents, gemcitabine (Gemzar) holds the most promise in the treatment of these difficult malignancies.

Entities:  

Mesh:

Year:  2002        PMID: 12164560

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  12 in total

1.  Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.

Authors:  Samuel J Wang; Andrew Lemieux; Jayashree Kalpathy-Cramer; Celine B Ord; Gary V Walker; C David Fuller; Jong-Sung Kim; Charles R Thomas
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Hiroki Ohge; Taijiro Sueda
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

3.  Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

Authors:  John W Nelson; A Paiman Ghafoori; Christopher G Willett; Douglas S Tyler; Theodore N Pappas; Bryan M Clary; Herbert I Hurwitz; Johanna C Bendell; Michael A Morse; Robert W Clough; Brian G Czito
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-19       Impact factor: 7.038

4.  Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.

Authors:  A Paiman Ghafoori; John W Nelson; Christopher G Willett; Junzo Chino; Douglas S Tyler; Herbert I Hurwitz; Hope E Uronis; Michael A Morse; Robert W Clough; Brian G Czito
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-23       Impact factor: 7.038

5.  Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.

Authors:  Naohiko Kohya; Kenji Kitahara; Kohji Miyazaki
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

6.  Side population cells in human gallbladder cancer cell line GBC-SD regulated by TGF-β-induced epithelial-mesenchymal transition.

Authors:  Zhifa Zhang; Feng Zhu; Ling Xiao; Min Wang; Rui Tian; Chengjian Shi; Renyi Qin
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-12-16

Review 7.  Chemotherapy for the biliary tract cancers: moving toward improved survival time.

Authors:  Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Journal:  J Gastrointest Cancer       Date:  2012-09

8.  Development and validation of a nomogram for survival benefit of lymphadenectomy in resected gallbladder cancer.

Authors:  Mingyu Chen; Jian Lin; Jiasheng Cao; Hepan Zhu; Bin Zhang; Angela Wu; Xiujun Cai
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

9.  Phase II study of S-1 in patients with advanced biliary tract cancer.

Authors:  H Ueno; T Okusaka; M Ikeda; Y Takezako; C Morizane
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

10.  Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma.

Authors:  Laurence Moureau-Zabotto; Olivier Turrini; Michel Resbeut; Jean-Luc Raoul; Marc Giovannini; Flora Poizat; Gilles Piana; Jean-Robert Delpero; Francois Bertucci
Journal:  BMC Cancer       Date:  2013-12-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.